Study on Relationships Between Expressions of Matrix Regulated Proteins and Count of Mast Cell in Pancreatic Cancer Tissues_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

YANG Zhulin , LI Yongguo , LIU Dongcai , DENG Xinghui , MIAO Xiongying , ZHONG Dewu.

Corresponding author：

Keywords：

Pancreatic tomor Extracellular matrix metalloproteinase inducer Matrix metalloproteinase Tissue inhibitors of- metalloproteinase Mast cell

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

【Abstract】Objective To investigate the expression of extracellular matrix metalloproteinase inducer(EMMPRIN)，matrix metalloproteinase-1(MMP1)，MMP9，tissue inhibitors of metalloproteinase-1(TIMP1) and the mast cell count (MCC) and to detect their clinicopathologic significance and relationship in pancreatic cancer tissues.
Methods Immunohistochemical method of avidin-biotin complex was used for those 5 targets on the routinely paraffinembedded sections of surgical resected specimen of 51 cases with pancreatic carcinoma.
Results The positive rates of EMMPRIN，MMP1，MMP9 and TIMP1 were 56.9%，54.9%，60.8% and 49.0% and its scoring were 2.5±1.5，2.3±1.9，2.4±1.6 and 1.9±1.6 respectively. The mean of MCC was (16.1±6.8)/HP in total cases. The positive rates or scorings of EMMPRIN，MMP1，MMP9 and MCC were significantly lower in high differentiated or without-metastatic cases than in low differentiated or with-metastatic ones(P＜0.05 or P＜0.01), and those targets (except MCC and scoring of MMP9) of middle differentiated ones were lower than those of low differentiated while that of TIMP1 was opposite(P＜0.01). The MCC showed significantly higher in the positive cases of EMMPRIN, MMP1 and MMP9 or negative cases of TIMP1 than in the negative ones of EMMPRIN, MMP1 and MMP9 or positive ones of TIMP1. The closely positive correlations were found among the MCC and the scoring of EMMPRIN, MMP1 and MMP9. The closely negative correlations existed among the scoring of TIMP1 and the other four targets.
Conclusion The MCC and the expressions of EMMPRIN, MMP1, MMP9 and TIMP1 might be important biological markers for reflecting the progression and the prognosis of pancreatic carcinoma. They might have co-regulated effects on the potentials of invasion and metastasis of pancreatic carcinoma or other malignant lesions.

Citation： YANG Zhulin,LI Yongguo,LIU Dongcai,DENG Xinghui,MIAO Xiongying,ZHONG Dewu.. Study on Relationships Between Expressions of Matrix Regulated Proteins and Count of Mast Cell in Pancreatic Cancer Tissues. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2005, 12(5): 488-491下转501. doi: Copy

1.	Parsons SL, Watson SA, Brown PD, et al. Matrix metalloproteinases [Ｊ]. Br J Surg, 1997; 84(2)∶160.
2.	Liabakk NB, Talbot I, Smith RA, et al. Matrix metalloprotease 2 (MMP2) and matrix metalloprotease 9 (MMP9) type IV collagenases in colorectal cancer [Ｊ]. Cancer Res， 1996; 56(1)∶190.
3.	BirkedalHansen B, Pavelic ZP, Gluckman JL, et al. MMP and TIMP gene expression in head and neck squamous cell carcinomas and adjacent tissues [Ｊ]. Oral Dis， 2000; 6(6)∶376.
4.	Davidson B, Goldberg I, Berner A, et al. EMMPRIN (extracellular matrix metalloproteinase inducer) is a novel marker of poor outcome in serous ovarian carcinoma [Ｊ]. Clin Exp Metastasis， 2003; 20(2)∶161.
5.	Toole BP. Emmprin (CD147), a cell surface regulator of matrix metalloproteinase production and function [Ｊ]. Curr Top Dev Biol， 2003; 54（6）∶371.
6.	Caudroy S, Polette M, NawrockiRaby B, et al. EMMPRINmediated MMP regulation in tumor and endothelial cells [Ｊ]. Clin Exp Metastasis， 2002; 19(8)∶697.
7.	Zucker S, Hymowitz M, Rollo EE, et al. Tumorigenic potential of extracellular matrix metalloproteinase inducer [Ｊ]. Am J（下转第501页）（上承第491页）Pathol， 2001; 158(6)∶1921.
8.	Molin D, Edstrom A, Glimelius I, et al. Mast cell infiltration correlates with poor prognosis in Hodgkin’s lymphoma [Ｊ]. Br J Haematol， 2002; 119(1)∶122.
9.	Aydin O, Dusmez D, Cinel L, et al. Immunohistological analysis of mast cell numbers in the intratumoral and peritumoral regions of prostate carcinoma compared to benign prostatic hyperplasia [Ｊ]. Pathol Res Pract， 2002; 198(4)∶267.
10.	Alexandrakis MG, Kyriakou DS, Seretakis D, et al. Inhibitory effect of retinoic acid on proliferation, maturation and tryptase level in human leukemic mast cells (HMC1) [Ｊ]. Int J Immunopathol Pharmacol， 2003; 16(1)∶43.
11.	Esposito I, Kleeff J, Bischoff SC, et al. The stem cell factorckit system and mast cells in human pancreatic cancer [Ｊ]. Lab Invest， 2002; 82(11)∶1481.
12.	Horny HP, Greschniok A, Jordan JH, et al. Chymase expressing bone marrow mast cells in mastocytosis and myelodysplastic syndromes: an immunohistochemical and morphometric study [Ｊ]. J Clin Pathol， 2003; 56(2)∶103.
13.	胡淳玲，喻伦银，陈德基等.大鼠实验性肺鳞癌癌变各阶段微血管密度及VEGF、FIK1表达的动态变化 [Ｊ]. 癌症, 2001； 20（7）∶713.

1. Parsons SL, Watson SA, Brown PD, et al. Matrix metalloproteinases [Ｊ]. Br J Surg, 1997; 84(2)∶160.
2. Liabakk NB, Talbot I, Smith RA, et al. Matrix metalloprotease 2 (MMP2) and matrix metalloprotease 9 (MMP9) type IV collagenases in colorectal cancer [Ｊ]. Cancer Res， 1996; 56(1)∶190.
3. BirkedalHansen B, Pavelic ZP, Gluckman JL, et al. MMP and TIMP gene expression in head and neck squamous cell carcinomas and adjacent tissues [Ｊ]. Oral Dis， 2000; 6(6)∶376.
4. Davidson B, Goldberg I, Berner A, et al. EMMPRIN (extracellular matrix metalloproteinase inducer) is a novel marker of poor outcome in serous ovarian carcinoma [Ｊ]. Clin Exp Metastasis， 2003; 20(2)∶161.
5. Toole BP. Emmprin (CD147), a cell surface regulator of matrix metalloproteinase production and function [Ｊ]. Curr Top Dev Biol， 2003; 54（6）∶371.
6. Caudroy S, Polette M, NawrockiRaby B, et al. EMMPRINmediated MMP regulation in tumor and endothelial cells [Ｊ]. Clin Exp Metastasis， 2002; 19(8)∶697.
7. Zucker S, Hymowitz M, Rollo EE, et al. Tumorigenic potential of extracellular matrix metalloproteinase inducer [Ｊ]. Am J（下转第501页）（上承第491页）Pathol， 2001; 158(6)∶1921.
8. Molin D, Edstrom A, Glimelius I, et al. Mast cell infiltration correlates with poor prognosis in Hodgkin’s lymphoma [Ｊ]. Br J Haematol， 2002; 119(1)∶122.
9. Aydin O, Dusmez D, Cinel L, et al. Immunohistological analysis of mast cell numbers in the intratumoral and peritumoral regions of prostate carcinoma compared to benign prostatic hyperplasia [Ｊ]. Pathol Res Pract， 2002; 198(4)∶267.
10. Alexandrakis MG, Kyriakou DS, Seretakis D, et al. Inhibitory effect of retinoic acid on proliferation, maturation and tryptase level in human leukemic mast cells (HMC1) [Ｊ]. Int J Immunopathol Pharmacol， 2003; 16(1)∶43.
11. Esposito I, Kleeff J, Bischoff SC, et al. The stem cell factorckit system and mast cells in human pancreatic cancer [Ｊ]. Lab Invest， 2002; 82(11)∶1481.
12. Horny HP, Greschniok A, Jordan JH, et al. Chymase expressing bone marrow mast cells in mastocytosis and myelodysplastic syndromes: an immunohistochemical and morphometric study [Ｊ]. J Clin Pathol， 2003; 56(2)∶103.
13. 胡淳玲，喻伦银，陈德基等.大鼠实验性肺鳞癌癌变各阶段微血管密度及VEGF、FIK1表达的动态变化 [Ｊ]. 癌症, 2001； 20（7）∶713.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Study on Relationships Between Expressions of Matrix Regulated Proteins and Count of Mast Cell in Pancreatic Cancer Tissues

Abstract Full text Figures/Tables Video References Cited by

Format

Content